Search

Displaying results 3131 - 3140 of 10000 in total
  1. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

  2. Drug

    Amber

    go.drugbank.com/drugs/DB14326
    Investigational

    Amber is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Categories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  3. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.

    Synonyms: N-β-(p-aminophenyl)ethylnormeperidine, N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine
  4. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L50036] Three aflibercept biosimilars—Yesafili (aflibercept-jbvf)[L53043] and Opuviz (aflibercept-yszy)[L53038], approved in May 2024, and Ahzantive (aflibercept-mrbb)[L53048], approved in July 2024

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL
  5. Drug

    Dicyclomine

    go.drugbank.com/drugs/DB00804
    ApprovedInvestigational

    Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]

  6. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

  7. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

  8. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated.

  9. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    Quinine (GLS-1200) was also investigated in clinical trials for its efficacy in preventing SARS-CoV-2 infection (NCT04408183, terminated) and is planned to be evaluated for preventing sinusitis after endoscopic … It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633.

  10. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.